289 related articles for article (PubMed ID: 23365557)
1. Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis.
Sun F; Yu K; Yang Z; Wu S; Zhang Y; Shi L; Ji L; Zhan S
Exp Diabetes Res; 2012; 2012():230624. PubMed ID: 23365557
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
4. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.
Sun F; Chai S; Li L; Yu K; Yang Z; Wu S; Zhang Y; Ji L; Zhan S
J Diabetes Res; 2015; 2015():157201. PubMed ID: 25688373
[TBL] [Abstract][Full Text] [Related]
5. GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.
Esposito K; Mosca C; Brancario C; Chiodini P; Ceriello A; Giugliano D
Curr Med Res Opin; 2011 Aug; 27(8):1519-28. PubMed ID: 21663496
[TBL] [Abstract][Full Text] [Related]
6. Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.
Ridge T; Moretto T; MacConell L; Pencek R; Han J; Schulteis C; Porter L
Diabetes Obes Metab; 2012 Dec; 14(12):1097-103. PubMed ID: 22734440
[TBL] [Abstract][Full Text] [Related]
7. [Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].
Lecube A; Bueno M; Suárez X
Med Clin (Barc); 2014 Sep; 143 Suppl 2():23-7. PubMed ID: 25437462
[TBL] [Abstract][Full Text] [Related]
8. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
Bettge K; Kahle M; Abd El Aziz MS; Meier JJ; Nauck MA
Diabetes Obes Metab; 2017 Mar; 19(3):336-347. PubMed ID: 27860132
[TBL] [Abstract][Full Text] [Related]
9. Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences.
Horowitz M; Aroda VR; Han J; Hardy E; Rayner CK
Diabetes Obes Metab; 2017 May; 19(5):672-681. PubMed ID: 28058769
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials.
Xue X; Ren Z; Zhang A; Yang Q; Zhang W; Liu F
Int J Clin Pract; 2016 Aug; 70(8):649-56. PubMed ID: 27456750
[TBL] [Abstract][Full Text] [Related]
11. A comparison of preferences for two GLP-1 products--liraglutide and exenatide--for the treatment of type 2 diabetes.
Polster M; Zanutto E; McDonald S; Conner C; Hammer M
J Med Econ; 2010; 13(4):655-61. PubMed ID: 21034377
[TBL] [Abstract][Full Text] [Related]
12. An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.
Madsbad S; Kielgast U; Asmar M; Deacon CF; Torekov SS; Holst JJ
Diabetes Obes Metab; 2011 May; 13(5):394-407. PubMed ID: 21208359
[TBL] [Abstract][Full Text] [Related]
13. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials.
Su B; Sheng H; Zhang M; Bu L; Yang P; Li L; Li F; Sheng C; Han Y; Qu S; Wang J
Endocrine; 2015 Feb; 48(1):107-15. PubMed ID: 25074632
[TBL] [Abstract][Full Text] [Related]
14. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
16. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.
Scott DA; Boye KS; Timlin L; Clark JF; Best JH
Diabetes Obes Metab; 2013 Mar; 15(3):213-23. PubMed ID: 22958381
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.
Owens DR; Monnier L; Bolli GB
Diabetes Metab; 2013 Dec; 39(6):485-96. PubMed ID: 24156868
[TBL] [Abstract][Full Text] [Related]
18. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
[TBL] [Abstract][Full Text] [Related]
20. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
